Literature DB >> 23996573

Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.

Shiyu Tong1, Minfeng Chen, Xiongbing Zu, Yuan Li, Wei He, Ye Lei, Wentao Liu, Lin Qi.   

Abstract

PURPOSE: To evaluate the role of two different approaches to perform laparoscopic RPLND: transperitoneal laparoscopic retroperitoneal lymph node dissection (TL-RPLND) and extraperitoneal laparoscopic retroperitoneal lymph node dissection (EL-RPLND).
MATERIALS AND METHODS: Between February 2003 and April 2013, 39 patients with nonseminomatous germ cell testicular tumors were treated by RPLND in our center. Twenty-one patients had TL-RPLND, and 18 patients had EL-RPLND. We performed a comprehensive retrospective study comparing TL-RPLND and EL-RPLND. Certain parameters, including operative time, estimated blood loss, perioperative complications, resected lymph nodes, postoperative intestinal function recovery time, ejaculation, and postoperative tumor markers, were abstracted and compared.
RESULTS: In the EL-RPLND and TL-RPLND groups, the operation times were 178 ± 31 and 207 ± 25 min; the amounts of estimated blood loss were 87 ± 26 and 111 ± 21 ml; the postoperative intestinal function recovery times were 1.2 ± 0.7 and 2.4 ± 0.6 days; the postoperative hospital stays were 5.8 ± 1.1 and 5.5 ± 1.4 days; and the numbers of resected lymph nodes were 16.2 ± 1.5 and 15.8 ± 1.6, respectively. No conversion from laparoscopic to open surgery occurred. No patient in either group received an intraoperative blood transfusion. Overall, two patients developed postoperative fever, and one developed abdominal distension. After a median follow-up of 45 months, no regional relapse or metastases occurred, but 4 patients at clinical stage II were treated successfully by three cycles of platinum-based postoperative chemotherapy. Currently, all patients show no evidence of disease.
CONCLUSION: Our results demonstrate that EL-RPLND was superior to the transperitoneal approach in terms of the operation time, estimated blood loss, and postoperative intestinal function recovery time, whereas no differences were observed in the number of lymph nodes resected. EL-RPLND was demonstrated to be safe and feasible, with satisfactory clinical outcomes when performed by experienced laparoscopic surgeons. Larger cohorts of patients with longer term follow-up are needed for further studies to determine the role of different approaches to L-RPLND.

Entities:  

Mesh:

Year:  2013        PMID: 23996573     DOI: 10.1007/s11255-013-0547-3

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  24 in total

Review 1.  Laparoscopic retroperitoneal lymph node dissection: technique.

Authors:  Jean-Baptiste Lattouf; Stephan Jeschke; Günter Janetschek
Journal:  BJU Int       Date:  2007-12       Impact factor: 5.588

2.  Resection of residual masses alone: an alternative in surgical therapy of metastatic testicular germ cell tumors after chemotherapy.

Authors:  H Ozen; S Ekici; S Sozen; A Ergen; S Tekgül; S Kendi
Journal:  Urology       Date:  2001-02       Impact factor: 2.649

3.  Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumors of the testis with introduction of a nerve sparing technique: description and results.

Authors:  E LeBlanc; A Caty; D Dargent; D Querleu; E Mazeman
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

Review 4.  Testicular cancer: a prototypic tumor of young adults.

Authors:  Brandon Hayes-Lattin; Craig R Nichols
Journal:  Semin Oncol       Date:  2009-10       Impact factor: 4.929

5.  During twenty years of Cisplatin-based therapy the face of nonseminomatous testicular germ cell tumors is still changing: an evaluation of presentation, management, predictive factors and survival.

Authors:  Julia Heinzelbecker; Michaela Katzmarzik; Christel Weiss; Lutz Trojan; Axel Haecker
Journal:  Int Braz J Urol       Date:  2013 Jan-Feb       Impact factor: 1.541

6.  Clinical outcomes in patients with stage I non-seminomatous germ cell cancer.

Authors:  Zhao-Jie Lv; Song Wu; Pei Dong; Kai Yao; Yin-Yin He; Yao-Ting Gui; Fang-Jian Zhou; Zhuo-Wei Liu; Zhi-Ming Cai
Journal:  Asian J Androl       Date:  2013-05-20       Impact factor: 3.285

7.  Nerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy.

Authors:  Norio Nonomura; Kazuo Nishimura; Natsuki Takaha; Hitoshi Inoue; Takeshi Nomoto; Youichi Mizutani; Masahiro Nakao; Akihiko Okuyama; Tsuneharu Miki
Journal:  Int J Urol       Date:  2002-10       Impact factor: 3.369

8.  Laparoscopic retroperitoneal lymph node dissection for low-stage testicular cancer.

Authors:  T A Skolarus; S B Bhayani; H C Chiang; S B Brandes; A S Kibel; J Landman; R S Figenshau
Journal:  J Endourol       Date:  2008-07       Impact factor: 2.942

9.  Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor?

Authors:  Evren Suer; Murat Mermerkaya; Ömer Gülpınar; Faraj Afandiyev; Sümer Baltacı; Kadir Türkölmez; Yaşar Bedük
Journal:  J Urol       Date:  2013-06-11       Impact factor: 7.450

10.  Current update of management of clinical stage I non seminomatous germ cell tumors of testis.

Authors:  T B Yuvaraja
Journal:  Indian J Surg Oncol       Date:  2012-03-20
View more
  2 in total

1.  Robot-assisted supine extraperitoneal retroperitoneal lymph node dissection: a novel approach for template dissection in post-chemotherapy residual mass in non-seminomatous germ cell tumours.

Authors:  Ginil Kumar Pooleri; Priyank Bijalwan; Rajesh Kesavan; Arun Philip; Pavithran Keechilat
Journal:  J Robot Surg       Date:  2018-05-04

Review 2.  Extraperitoneal robot-assisted laparoscopic retroperitoneal lymph node dissection for early-stage testicular nonseminomatous germ cell tumors: A case report and literature review.

Authors:  Jie Qin; Ping Wang; Taile Jing; Debo Kong; Dan Xia; Shuo Wang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.